AB0402 Efficacy of Iguratimod Alone or in Combination with Methotrxate in Patients with Rheumatoid Arthritis. (15th July 2016)

• Record Type: Journal Article
• Authors: Kawamoto, T.; Umibe, T.; Iida, S.
• Is Part Of: Annals of the rheumatic diseases. Volume 75(2016)Supplement 2
• Page Start: 1043
• Page End: 1044
• Publication Date: 2016-07-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2016-eular.2506
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: It has reported that Iguratimod (IGU), one of methanesulfonanilide of anti-inflamamatory agents, can inhibit anti-arthritic activity of rheumatoid arthritis (RA). IGU was approved for rheumatoid arthritis patients with inappropriate response to conventional treatments in Japan in September 2012. Objectives: We aimed to assess the efficacy of IGU alone or in combination with Methotrxate (MTX) in patients with rheumatoid Arthritis Methods: Patients who had an inadequqte response to MTX were enrolled. From December 2012, forty nine patients treated with IGU were analyzes retrospectively; 17 of 49 patients were treated with only IGU, 32 of 49 patients were treated with add-on IGU in combination with MTX. Disease activity and clinical response were assessed by disease activity score 28/ESR (DAS28-ESR) and EULAR response criteria, respectively. The DAS28-ESR, CRP, SDAI, CDAI at 1, 2, 3, 6, 12, 24 months from administration of IGU were examined. Results: The average amount of IGU is 40.7mg in MTX group and 41.3mg in non- MTX group. The average amount of MTX was 7mg. After follow up 24 months, escape cases was six cases. The DAS28-ESR. After 12 months of treatment, The DAS28-ESR was decreased from4.32 to 2.37 significantly in MTX group ( P <0.01), and also decreased from4.23 to 2.37 significantly in non-MTX group ( P <0.01). According to EULAR response criteria at 12 months, The DAS28-ESR remission was observed in 46.9% of patients in MTX group and 52.9% in non- MTX group. CRP decreased from1.9 to 0.7 significantly in MTX group ( P <0.01), and also decreased from 2.1 to 0.8 significantly in non-MTX group ( P <0.05).There was no significant difference between the two groups. Conclusions: Based on these results, we can conclude that the treatment of IGU is effective and well tolerated, and represents a new option for RA patients, including patient with inadequqte response to MTX. References: Liang-jing Lu, et al. Multicenter, dandomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis. Rheumatol 61, No. 7 July 2009:979–987 Y Aikawa, et al.An anti-rheumatic agent T-614 inhibits NF-kB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IkBα degration. Inflammation Research April 2002, Vol51 4:188–194 Xu Y, et al Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid.Medators Inflamm 2015 Dec 2.:1155 Okamura K, et al. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol2015 Mar;25(2):235–40 Disclosure of Interest: None declared